Current Report Filing (8-k)
February 06 2019 - 7:58AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported)
February 6, 2019
EYENOVIA, INC.
(Exact name of registrant as specified
in its charter)
|
Delaware
(State or other jurisdiction of incorporation)
|
|
|
|
|
001-38365
|
|
47-1178401
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
295 Madison Avenue, Suite 2400, New
York, NY 10017
(Address of principal executive offices)
(Zip Code)
Registrant's telephone number, including
area code
917-289-1117
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether
the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (
§
230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (
§
240.12b-2 of
this chapter).
Emerging Growth Company
x
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
On February 6, 2019, Eyenovia, Inc. (the “Company”)
issued a press release announcing that the U.S. Food and Drug Administration has accepted the Company’s Investigational New
Drug Application to initiate the Company’s Phase III trial for MicroPine (the CHAPERONE study) to reduce the progression
of myopia in children. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
EYENOVIA, INC.
|
|
|
|
|
|
Date: February 6, 2019
|
By:
|
/s/ John Gandolfo
|
|
|
|
Name: John Gandolfo
|
|
|
|
Title: Chief Financial Officer
|
|
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From Apr 2024 to May 2024
Eyenovia (NASDAQ:EYEN)
Historical Stock Chart
From May 2023 to May 2024